U.S. markets closed
  • S&P Futures

    4,111.00
    -8.50 (-0.21%)
     
  • Dow Futures

    33,619.00
    -63.00 (-0.19%)
     
  • Nasdaq Futures

    13,801.75
    -27.75 (-0.20%)
     
  • Russell 2000 Futures

    2,234.60
    -4.60 (-0.21%)
     
  • Crude Oil

    59.56
    +0.24 (+0.40%)
     
  • Gold

    1,740.90
    -3.90 (-0.22%)
     
  • Silver

    25.22
    -0.11 (-0.43%)
     
  • EUR/USD

    1.1895
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • Vix

    16.69
    -0.26 (-1.53%)
     
  • GBP/USD

    1.3687
    -0.0019 (-0.14%)
     
  • USD/JPY

    109.5580
    -0.0920 (-0.08%)
     
  • BTC-USD

    60,029.82
    -305.27 (-0.51%)
     
  • CMC Crypto 200

    1,282.02
    +54.48 (+4.44%)
     
  • FTSE 100

    6,915.75
    -26.47 (-0.38%)
     
  • Nikkei 225

    29,739.13
    -28.93 (-0.10%)
     

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of GW Pharmaceuticals plc (NASDAQ:GWPH)

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

BALA CYNWYD, PA / ACCESSWIRE / February 3, 2021 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of GW Pharmaceuticals plc ("GW Pharma" or the "Company") (NASDAQ:GWPH) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Jazz Pharmaceuticals plc ("Jazz") (NASDAQ:JAZZ). Under the terms of the agreement, GW Pharma shareholders will receive only $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares for each share of GW Pharma they own.

The investigation concerns whether the GW Pharma Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Jazz is underpaying for the Company. For example, at least one wall street analyst has set a price target of $275.00 per share for GW Pharma stock.

If you own shares of GW Pharma stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/gw-pharmaceuticals-plc-nasdaq-gwph/, or call toll free 855-576-4847.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC



View source version on accesswire.com:
https://www.accesswire.com/627740/SHAREHOLDER-NOTICE-Brodsky-Smith-LLC-Announces-an-Investigation-of-GW-Pharmaceuticals-plc-NASDAQGWPH